<?xml version="1.0" encoding="UTF-8"?>
<document id="27988457">
	<sentence id="s1" text="Lucitanib is a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors 1 to 3 (VEGFR1 to 3), platelet derived growth factor α/β (PDGFRα/β) and FGFR1-3 tyrosine kinases and has demonstrated activity in a phase I/II clinical study, with objective RECIST responses in breast cancer patients with FGFR1 or FGF3/4/19 gene amplification, as well as in patients anticipated to benefit from anti-angiogenic agents.">
		<entity id="s1.e1" charOffset="79-83"
			type="GENE" text="VEGF" ontology_id="7422"/>
		<entity id="s1.e2" charOffset="167-172"
			type="GENE" text="FGFR1" ontology_id="2260"/>
		<entity id="s1.e3" charOffset="296-302"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e3" pgr="false"/>
		<pair id="s1.p2" e1="s1.e2"
		    e2="s1.e3" pgr="true"/>
	</sentence>
	<sentence id="s2" text="We report here the in vitro and in vivo antitumor activity of lucitanib in experimental models with or without FGFR1/2 amplification or mutations.">
		<entity id="s2.e1" charOffset="44-49"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s2.e2" charOffset="111-116"
			type="GENE" text="FGFR1" ontology_id="2260"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="true"/>
	</sentence>
	<sentence id="s3" text="In cell assays, lucitanib potently inhibited the growth of tumor cell lines with amplified FGFR1 or mutated/amplified FGFR2.">
		<entity id="s3.e1" charOffset="59-64"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s3.e2" charOffset="91-96"
			type="GENE" text="FGFR1" ontology_id="2260"/>
		<entity id="s3.e3" charOffset="118-123"
			type="GENE" text="FGFR2" ontology_id="2263"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e2" pgr="true"/>
		<pair id="s3.p2" e1="s3.e1"
		    e2="s3.e3" pgr="true"/>
	</sentence>
	<sentence id="s4" text="Notably, in two lung cancer models with FGFR1 amplification, the antitumor efficacy was higher, suggesting that the simultaneous inhibition of VEGF and FGF receptors in FGFR1 dependent tumors can be therapeutically advantageous.">
		<entity id="s4.e1" charOffset="21-27"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s4.e2" charOffset="40-45"
			type="GENE" text="FGFR1" ontology_id="2260"/>
		<entity id="s4.e3" charOffset="69-74"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s4.e4" charOffset="143-147"
			type="GENE" text="VEGF" ontology_id="7422"/>
		<pair id="s4.p1" e1="s4.e3"
		    e2="s4.e4" pgr="false"/>
		<pair id="s4.p2" e1="s4.e2"
		    e2="s4.e3" pgr="true"/>
		<pair id="s4.p3" e1="s4.e1"
		    e2="s4.e4" pgr="false"/>
		<pair id="s4.p4" e1="s4.e5"
		    e2="s4.e2" pgr="true"/>
	</sentence>
	<sentence id="s5" text="Similar antitumor activity was observed in FGFR2 wild-type and amplified or mutated xenograft models.">
		<entity id="s5.e1" charOffset="12-17"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s5.e2" charOffset="43-48"
			type="GENE" text="FGFR2" ontology_id="2263"/>
		<pair id="s5.p1" e1="s5.e1"
		    e2="s5.e2" pgr="true"/>
	</sentence>
</document>
